Letter: The Prognostic Role of IGF-1 in Chronic Liver Disease-Authors' Reply

被引：0
|
作者：
Hartl, Lukas [1 ,2 ,3 ]
Schwarz, Michael [1 ,2 ]
Simbrunner, Benedikt [1 ,2 ,3 ,4 ]
Jachs, Mathias [1 ,2 ,3 ]
Wolf, Peter [5 ]
Bauer, David Josef Maria [1 ,2 ]
Scheiner, Bernhard [1 ,2 ,3 ]
Balcar, Lorenz [1 ,2 ,3 ]
Semmler, Georg [1 ,2 ,3 ]
Hofer, Benedikt Silvester [1 ,2 ,3 ,4 ]
Dominik, Nina [1 ,2 ,3 ]
Marculescu, Rodrig [6 ]
Trauner, Michael [1 ,3 ]
Mandorfer, Mattias [1 ,2 ,3 ]
Reiberger, Thomas [1 ,2 ,3 ,4 ]
机构：
[1] Med Univ Vienna, Dept Med 3, Div Gastroenterol & Hepatol, Vienna, Austria
[2] Med Univ Vienna, Dept Med 3, Div Gastroenterol & Hepatol, Vienna Hepat Hemodynam Lab, Vienna, Austria
[3] Med Univ Vienna, Dept Med 3, Div Gastroenterol & Hepatol, Clin Res Grp MOTION, Vienna, Austria
[4] Med Univ Vienna, Christian Doppler Lab Portal Hypertens & Liver Fib, Vienna, Austria
[5] Med Univ Vienna, Dept Med 3, Div Endocrinol, Vienna, Austria
[6] Med Univ Vienna, Dept Lab Med, Vienna, Austria
来源：
ALIMENTARY PHARMACOLOGY & THERAPEUTICS | 2025年 / 61卷 / 01期
关键词：
D O I：
10.1111/apt.18368
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：228 / 229
页数：2
相关论文
共 50 条
  • [1] Letter: The Prognostic Role of IGF-1 in Chronic Liver Disease
    Osama, Muhammad
    Ubaid, Safiyyah
    Ubaid, Maryam
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2025, 61 (01) : 226 - 227
  • [2] Letter: Potential impact of Helicobacter pylori infection on oesophageal disorders in chronic liver disease-Authors' reply
    Idalsoaga, Francisco
    Diaz, Luis Antonio
    Ayares, Gustavo
    Cabrera, Daniel
    Chahuan, Javier
    Monrroy, Hugo
    Halawi, Houssam
    Arrese, Marco
    Arab, Juan Pablo
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2024, 60 (08) : 1141 - 1142
  • [3] Letter: vedolizumab for autoimmune liver disease associated inflammatory bowel disease-Authors' reply
    Christensen, B.
    Gibson, P. R.
    Rubin, D. T.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2018, 47 (10) : 1423 - 1424
  • [4] Letter: rationalising aminosalicylates in inflammatory bowel disease-authors' reply
    Chapman, Thomas P.
    Frias Gomes, Catarina
    Louis, Edouard
    Colombel, Jean-Frederic
    Satsangi, Jack
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2020, 52 (10) : 1621 - 1621
  • [5] Letter: diagnostic delay in inflammatory bowel disease-Authors' reply
    Pollok, Richard
    Baillie, Samantha
    Jayasooriya, Nishani
    Blackwell, Jonathan
    Petersen, Irene
    Bottle, Alex
    Saxena, Sonia
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2023, 57 (10) : 1205 - 1206
  • [6] Letter: pancreatic involvement in inflammatory bowel disease-authors' reply
    Massironi, Sara
    Vigano, Chiara
    Danese, Silvio
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2022, 56 (02) : 371 - 371
  • [7] Letter: effect of HCV eradication on cardiovascular disease-Authors' reply
    Licata, Anna
    Soresi, Maurizio
    Novo, Giuseppina
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2018, 48 (10) : 1169 - 1170
  • [8] Crystalising the burden of steatotic liver disease-Authors' reply
    Schneider, Carolin V.
    Schneider, Kai Markus
    Loomba, Rohit
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2024, 59 (10) : 1294 - 1295
  • [9] Letter: proving the benefit of exercise intervention in metabolic associated fatty liver disease-authors' reply
    O'Gorman, Philip
    Naimimohasses, Sara
    Monaghan, Ann
    Kennedy, Megan
    Finn, Stephen P.
    Moore, J. Bernadette
    Gormley, John
    Norris, Suzanne
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2020, 52 (08) : 1426 - 1427
  • [10] Role of IGF-1 and glycaemic control in diabetic retinopathy: the authors reply
    Chen, Harn-Shen
    EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2012, 42 (07) : 805 - 806
12345